Medical management of primary open-angle glaucoma: Best practices associated with enhanced patient compliance and persistency

Patient Preference and Adherence

Volumn 2, Issue , 2008, Pages 303-313

  Kulkarni, Sadhana V ^a,b   Damji, Karim F ^a,b   Buys, Yvonne M ^c  

^a UNIVERSITY OF OTTAWA EYE INSTITUTE   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Compliance; Glaucoma; Medication therapy management; Persistence

Indexed keywords

EID: 79953716508     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S4163     Document Type: Review

References (54)

1. [AAO] American Academy of Ophthalmology. 2005. Preferred Practice Pattern: Primary Open Angle Glaucoma. San Francisco, CA. American Academy of Ophthalmology.
2. [CNTG] Collaborative Normal-Tension Glaucoma Study Group. 1998. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol, 126:498-505.
3. Aspinall P. A, Johnson ZK, Azuara-Blanco A, et al. 2008. Evaluation of quality of life and priorities of patients with glaucoma. Invest Ophthalmol Vis Sci, 49:1907-15.
4. Best S.J. 2007. Does persistency truly equate to compliance? Clin Exper Ophthalmol, 35:593.
5. Bhargava J. S, Patel B, Foss AJ, et al. 2006. Views of glaucoma patients on aspects of their treatment: an assessment of patient preference by conjoint analysis. Invest Ophthalmol Vis Sci, 47:2885-8.
6. Blondeau P., Esper P, Mazerolle E. 2007. An information session for glaucoma patients. Can J Ophthalmol, 42:816-20.
7. Bour T., Blanchard F, Segal A. 1993. [Therapeutic observance and life of patients with primary open-angle glaucoma. Apropos of 341 cases in the department of Marne.]. J Fr Ophtalmol, 16(6-7):380-91.
8. Buller A. J, Morgan LH, Hercules BL. 2007. Patients prefer once-daily glaucoma drops. Graefes Arch Clin Exper Ophthalmol, 245:293-4.
9. Damji K. F, Behki R, Wang L; Target IOP Workshop. 2003. Canadian perspectives in glaucoma management: setting target intraocular pressure range. Can J Ophthalmol, 38:189-97.
10. Danesh-Meyer HV, Deva NC, Slight C, et al. 2008. What do people with glaucoma know about their condition? A comparative cross-sectional incidence and prevalence survey. Clin Exper Ophthalmol, 36:13-8.
11. Detry-Morel M. 2006. [Compliance and persistence.]. J Fr Ophtalmol, 29:216-25.
12. Friedman D. S, Hahn SR, Gelb L, et al. 2008. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology, 115:1320-7.
13. Friedman D. S, Jampel HD, Munoz B, et al. 2006. The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol, 124:1625-30.
14. Friedman D. S, Wolfs RC, O'Colmain BJ, et al, Eye Diseases Prevalence Research Group. 2004. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol, 122:532-8.
15. Girma T., Courtright P, Mengistu F, et al. 2006. A placebo controlled double blind clinical trial of mitomycin C in primary trabeculectomy in Ethiopian patients. Ethiop Med J, 44:253-6.
16. Goldberg L. D, Walt J. 2006. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics, 24:251-64.
17. Grol R., Grimshaw J. 1999. Evidence-based implementation of evidence-based medicine. Jt Comm J Qual Improv, 25:503-13.
18. Haymes S. A, LeBlanc RP, Nicolela MT, et al. 2007. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci, 48:1149-55.
19. Jampel H. D, Parekh P, Johnson E, et al. 2005. Chart documentation by general physicians of the glaucoma medications taken by their patients. Am J Ophthalmol, 140:344-5.
20. Janz N. K, Wren PA, Lichter PR, et al; CIGTS Study Group. 2001. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology, 108:1954-65.
21. Joyce A. C, Ahuja R, Anita B, et al. 2008. Medication compliance and persistence: terminology and definitions. Value Health, 11:44-7.
22. Juzych M. S, Randhawa S, Shukairy A, et al. 2008. Functional health literacy in patients with glaucoma in urban settings. Arch Ophthalmol, 126:718-24.
23. Kass M. A, Heuer DK, Higginbotham EJ, et al. 2002. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol, 120:701-13.
24. Kharod B. V, Johnson PB, Nesti HA, et al. 2006. Effect of written instructions on accuracy of self-reporting medication regimen in glaucoma patients. J Glaucoma, 15:244-7.
25. Kholdebarin R., Jin Y, Campbell RJ, et al. 2008. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol, 43:454-61.
26. Lacey J., Cate H, Broadway DC. 2008. Barriers to adherence with glaucoma medications: a qualitative research study. Eye, Apr 25. [Epub ahead of print]
27. Lachaine J., Hodge WG, Steffensen I, et al. 2008. Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. Can J Ophthalmol, 43:33-41.
28. LeBlanc RP, Canadian Glaucoma Strategy Forum. 2007. A Canadian glaucoma strategy. Can J Ophthalmol, 42:60-5.
29. Leske M. C, Connell AM, Schachat AP, et al. 1994. The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol, 112:821-9.
30. Leske M. C, Heijl A, Hussein M, et al, Early Manifest Glaucoma Trial Group. 2003. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol, 121:48-56.
31. Mansberger S. L, Hughes BA, Gordon MO, et al; Ocular Hypertension Treatment Study Group. 2007. Comparison of initial intraocular pressure response with topical beta-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study. Arch Ophthalmol, 125:454-9.
32. Muir K. W, Santiago-Turla C, Stinnett SS, et al. 2006. Health literacy and adherence to glaucoma therapy. Am J Ophthalmol, 142:223-6.
33. Nemesure B., Honkanen R, Hennis A, et al; Barbados Eye Studies Group. 2007. Incident open-angle glaucoma and intraocular pressure. Ophthalmology, 114:1810-15.
34. [NIH] US National Institutes of Health. 2008. Clinical Trials Search [online]. Accessed on Sept 29, 2008. URL: http://clinicaltrials.gov/ show/NCT00508469.
35. Nordstrom B. L, Friedman DS, Mozaffari E, et al. 2005. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol, 140:598-606.
36. Obstbaum S. A, Cioffi GA, Krieglstein GK, et al. 2004. Gold standard medical therapy for glaucoma: defining the criteria identifying measures for an evidence-based analysis. Clin Ther, 26:2102-20.
37. Parikh R. S, Parikh SR, Navin S, et al. 2008. Practical approach to medical management of glaucoma. Indian J Ophthalmol, 56:223-30.
38. Quigley H.A. 1996. Number of people with glaucoma worldwide. Br J Ophthalmol, 80:389-93.
39. Quigley H. A, Friedman DS, Hahn SR. 2007. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology, 114:1599-606.
40. Quigley H. A, Vitale S. 1997. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci, 38:83-91.
41. Robin A. L, Novack GD, Covert DW, et al. 2007. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol, 144:533-40.
42. Rouland J. F, Berdeaux G, Lafuma A. 2005a. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review. Drugs Aging, 22:315-21.
43. Rouland J. F, Le Pen C, Benhaddi H, et al; Glaucoma Study Group. 2005b. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years. Eur J Ophthalmol, 15:562-80.
44. Salyani A., Birt C. 2005. Evaluation of an eye drop guide to aid self-administration by patients experienced with topical use of glaucoma medication. Can J Ophthalmol, 40:170-4.
45. Schmier J. K, Halpern MT, Jones ML. 2007. The economic implications of glaucoma: a literature review. Pharmacoeconomics, 25:287-308.
46. Schwartz G. F, Platt R. 2002. Measuring persistency and intraocular pressure-controlled days in patients receiving topical glaucoma medications. Am J Manage Care, 8(10 Suppl):S278-80.
47. Shaw M.E. 2005. Increasing compliance with glaucoma therapy: "so, convince me I have something wrong with my eyes". Insight, 30:7-9.
48. Shibuya T., Kashiwagi K, Tsukahara S. 2003. Comparison of efficacy and tolerability between two gel-forming timolol maleate ophthalmic solutions in patients with glaucoma or ocular hypertension. Ophthalmologica, 217:31-8.
49. Singh K., Lee BL, Wilson MR, Glaucoma Modified RAND-Like Methodology Group. 2008. A panel assessment of glaucoma management: modification of existing RAND-like methodology for consensus in ophthalmology. Part II: Results and interpretation. Am J Ophthalmol, 145:575-81.
50. Sood N. N, Kumar H, Patil ND, et al. 1991. Medical and socio-economic aspects of long term therapy of open angle glaucoma. Indian J Ophthalmol, 39:91-3.
51. Thomas R., Sekhar GC, Kumar RS. 2004. Glaucoma management in developing countries: medical, laser, and surgical options for glaucoma management in countries with limited resources. Curr Opin Ophthalmol, 15:127-31.
52. Tingey D., Bernard LM, Grima DT, et al. 2005. Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension. Can J Ophthalmol, 40:161-9.
53. Tsai J. C, McClure CA, Ramos SE, et al. 2003. Compliance barriers in glaucoma: a systematic classification. J Glaucoma, 12:393-8.
54. Vicente C., Walker J, Buys Y, et al. 2004. Association between mean intraocular pressure, disease stability and cost of treating glaucoma in Canada. Curr Med Res Opin, 20:1245-51.